These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33832957)

  • 1. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial.
    Qu L; Liang X; Tian G; Zhang G; Wu Q; Huang X; Cui Y; Liu Y; Shen Z; Xiao C; Qin Y; Miao H; Zhang Y; Li Z; Ye S; Zhang X; Yang J; Cao G; Li Y; Yang G; Hu J; Wang X; Li Z; Li Y; Zhang X; Zhang G; Chen L; Hua W; Yu M; Lu C; Zhang X; Jiang H
    Diabetes Care; 2021 Jun; 44(6):1324-1333. PubMed ID: 33832957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for Treatment of Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Study.
    Qu L; Liang XC; Tian GQ; Zhang GL; Wu QL; Huang XM; Cui YZ; Liu YL; Shen ZF; Ma GQ; Lu H; Li Y; Jiang H; Yang XY; Zhang GD; Yang CH
    Chin J Integr Med; 2022 Apr; 28(4):304-311. PubMed ID: 35048240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blinded, Double-Dummy, Active-Controlled, and Multiple-Dose Clinical Study Comparing the Efficacy and Safety of Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet and Acarbose in Individuals with Type 2 Diabetes Mellitus.
    Li M; Huang X; Ye H; Chen Y; Yu J; Yang J; Zhang X
    Evid Based Complement Alternat Med; 2016; 2016():7121356. PubMed ID: 27547230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of mulberry twig alkaloids(Sangzhi alkaloids) and metformin on blood glucose fluctuations in combination with premixed insulin-treated patients with type 2 diabetes.
    Meng Z; Xu C; Liu H; Gao X; Li X; Lin W; Ma X; Yang C; Hao M; Zhao K; Hu Y; Wang Y; Kuang H
    Front Endocrinol (Lausanne); 2023; 14():1272112. PubMed ID: 38027146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of acarbose chewable tablet in patients with type 2 diabetes: a multicentre, randomized, double-blinded, double-dummy positive controlled trial.
    Wu QL; Liu YP; Lu JM; Wang CJ; Yang T; Dong JX; Li CJ; Ma JH; Xue YM; Sun RH; Wei D; Tian HM
    J Evid Based Med; 2012 Aug; 5(3):134-8. PubMed ID: 23672220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
    Wang W; Ning G; Ma J; Liu X; Zheng S; Wu F; Xu L; O'Neill EA; Fujita KP; Engel SS; Kaufman KD; Shankar RR
    Curr Med Res Opin; 2017 Apr; 33(4):693-699. PubMed ID: 28035868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
    Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
    Coniff RF; Shapiro JA; Seaton TB; Hoogwerf BJ; Hunt JA
    Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Nauck M; Weinstock RS; Umpierrez GE; Guerci B; Skrivanek Z; Milicevic Z
    Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
    Jabbour SA; Frías JP; Hardy E; Ahmed A; Wang H; Öhman P; Guja C
    Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
    Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
    Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
    Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ
    J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
    Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin.
    Phillips P; Karrasch J; Scott R; Wilson D; Moses R
    Diabetes Care; 2003 Feb; 26(2):269-73. PubMed ID: 12547847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
    Halimi S; Le Berre MA; Grangé V
    Diabetes Res Clin Pract; 2000 Sep; 50(1):49-56. PubMed ID: 10936668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
    Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.